Greenwich LifeSciences, Inc.
For the period ended Dec 31, 2025. Filed Jun 1, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Jun 1, 2026
GLSI$16.07-2.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets as of December 31, 2025 and 2024
BALANCE SHEETS
AS OF DECEMBER 31, 2025 AND 2024
| 2025 | 2024 (As Restated) | |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash | $6,178,021 | $4,091,990 |
| Total current assets | 6,178,021 | 4,091,990 |
| Acquired patents, net | — | 1,779 |
| Total assets | $6,178,021 | $4,093,769 |
| Liabilities and stockholders’ equity | ||
| Current liabilities | ||
| Accounts payable & accrued interest | $4,874,489 | $2,802,946 |
| Deferred compensation | 673,819 | 306,281 |
| Unreimbursed expenses | 276,496 | 75,916 |
| Total current liabilities | 5,824,804 | 3,185,143 |
| Total liabilities | 5,824,804 | 3,185,143 |
| Stockholders’ equity | ||
| Common stock, $0.001 par value; 100,000,000 shares authorized; 14,298,446 and 13,152,729 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | 14,299 | 13,153 |
| Additional paid-in capital | 87,475,924 | 68,674,261 |
| Accumulated deficit | (87,137,006) | (67,778,788) |
| Total stockholders’ equity | 353,217 | 908,626 |
| Total liabilities and stockholders’ equity | $6,178,021 | $4,093,769 |
Table of Contents
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.